查看购物车
  • Traditional Chinese
  • English
  • Japanese
北美体外诊断市场预测至 2030 年 - 区域分析 - 按产品和服务、技术、应用和最终用户
市场调查报告书
商品编码
1463559

北美体外诊断市场预测至 2030 年 - 区域分析 - 按产品和服务、技术、应用和最终用户

North America In-Vitro Diagnostics Market Forecast to 2030 - Regional Analysis - by Product & Services, Technology, Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 112 Pages | 订单完成后即时交付

价格

北美体外诊断市场预计将从2022年的212.0707亿美元成长到2030年的331.8341亿CAGR。

COVID-19 大流行期间床边检测的成长和 IVD 需求的激增推动了北美体外诊断市场

即时检测 (POCT) 是体外诊断市场的关键机会，以其便携式和快速的诊断能力彻底改变了医疗保健服务。这些测试在患者所在地或附近进行，可以立即提供结果，从而能够及时做出临床决策。有几个因素推动 POCT 的成长。

首先，急诊室、诊所和家庭护理等医疗机构对方便快速的诊断解决方案的需求推动了 POCT 的扩张。其次，技术进步促进了紧凑且用户友好的 POCT 设备的发展。

此外，COVID-19 大流行凸显了快速、方便的诊断的重要性。这次疫情加速了 COVID-19 即时检测的部署和利用，展示了 POCT 在全球范围内管理传染病的相关性和潜力。这项经验加速了 POCT 的研发，进一步推动了便携式测试解决方案的创新和投资。

用于诊断传染病的 IVD 包括免疫测定和分子测定。诊断公司也致力于快速改进其管理 COVID-19 的产品。此外，监管机构对其标准进行了临时修订或修改，这有利于在大流行期间推出新的体外诊断设备。由于这些政府倡议，对分子诊断和免疫测定的需求激增。因此，由于对即时诊断 (POC) 诊断和实验室检测程序的需求不断增长，COVID-19 大流行使体外诊断市场受益。

北美体外诊断市场概况

北美地区包括美国、加拿大和墨西哥。按地理划分，它在体外诊断市场中占有最大份额。该地区所有三个国家都见证了对体外诊断的巨大需求。某些因素，例如慢性病和传染病的盛行率不断上升、对有效疾病诊断的关注以及对先进医疗保健系统的更高需求，正在推动该地区体外诊断的采用。美国占据北美体外诊断市场的最大份额。癌症和心血管疾病等慢性病是美国残疾和死亡的主要原因。根据国家慢性病预防和健康促进中心的数据，全国十分之六的人至少患有一种慢性病。根据美国疾病管制与预防中心 (CDC) 的数据，2021 年，美国约有 1,820 万名 20 岁及以上的成年人患有冠状动脉疾病 (CAD)。心臟病是该国人民死亡的主要原因。此外，美国医院协会估计约 1.33 亿人至少患有一种慢性病，预计到 2030 年这一数字将达到 1.7 亿人。对预防保健的日益重视以及医疗保健设施的普及将进一步推动未来几年的市场成长。

随着患者数量的不断增加，对体外诊断工具的需求呈指数级增长，市场参与者专注于开发能够快速检查的先进诊断系统。例如，2019 年 2 月，美国诊断服务公司 Grail 获得了微软和亚马逊 15 亿美元的财务援助，旨在开发快速癌症检测的新技术。此外，发达的医疗基础设施和不断增加的支出带来的广泛技术进步正在为该国体外诊断市场的成长创造利润丰厚的机会。例如，2019年7月，体外诊断市场的知名参与者之一Sysmex America, Inc.在第71届AACC年度科学会议和临床实验室博览会上展示了其名为PS-10的新型集成体外诊断机在加州阿纳海姆举办。该机器设计用于执行复杂的实验室测试、常规细胞计数和血液学评估。同样，2020 年 5 月，Bio-Rad Laboratories Inc. 的 SARS-CoV-2 液滴数位 PCR (ddPCR) 检测试剂盒获得美国食品药物管理局 (FDA) 的紧急使用授权 (EUA)。 SARS-CoV-2 ddPCR 测试在 Bio-Rad 的 QX200 和 QXDx ddPCR 系统上运行。

北美体外诊断市场收入及 2030 年预测（百万美元）

北美体外诊断市场细分

北美体外诊断市场分为产品和服务、技术、应用、最终用户和国家。

根据产品和服务，北美体外诊断市场分为试剂和试剂盒、仪器以及软体和服务。 2022年，试剂和试剂盒细分市场占据北美体外诊断市场的最大份额。

根据技术，北美体外诊断市场分为免疫测定/免疫化学、临床化学、分子诊断、微生物学、血糖自我监测、凝血和止血、血液学、尿液分析等。 2022 年，免疫分析/免疫化学领域占据北美体外诊断市场的最大份额。

根据应用，北美体外诊断市场分为传染病、糖尿病、肿瘤学、心臟病学、自体免疫疾病、肾臟病学等。 2022年，传染病领域占据北美体外诊断市场的最大份额。

根据最终用户，北美体外诊断市场分为医院、实验室、家庭护理等。 2022年，医院细分市场在北美体外诊断市场中占据最大份额。

根据国家/地区，北美体外诊断市场分为美国、加拿大和墨西哥。 2022年，美国将主导北美体外诊断市场。

Abbott Laboratories、Becton Dickinson and Co、bioMerieux SA、Bio-Rad Laboratories Inc、Danaher Corp、F. Hoffmann-La Roche Ltd、Qiagen NV、Siemens AG、Sysmex Corp 和Thermo Fisher Scientific Inc 是在这些地区运营的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美体外诊断市场 - 主要产业动态

  • 主要市场驱动因素
    • 慢性病和传染病的盛行率不断增加
    • COVID-19 大流行期间床边检测的成长和 IVD 需求的激增
  • 市场约束
    • 监理框架和报销政策不足
  • 市场机会
    • IVD 与数位健康科技的整合
  • 未来的趋势
    • 对个人化医疗和基因组学的需求不断增长

第 5 章：体外诊断市场 - 北美市场分析

  • 北美体外诊断市场收入，2022 - 2030

第 6 章：北美体外诊断市场 - 2030 年收入和预测 - 按产品和服务

  • 概述
  • 2022 年和 2030 年北美体外诊断市场收入份额（按产品和服务划分）
  • 试剂和试剂盒
  • 软体和服务
  • 仪器

第 7 章：北美体外诊断市场 - 收入和 2030 年预测 - 按技术分类

  • 概述
  • 北美体外诊断市场收入份额，按技术划分 2022 年和 2030 年 (%)
  • 免疫测定/免疫化学
  • 临床化学
  • 分子诊断
  • 微生物学
  • 血糖自我监测
  • 凝血与止血
  • 血液学
  • 尿液分析
  • 其他的

第 8 章：北美体外诊断市场 - 2030 年收入和预测 - 按应用

  • 概述
  • 2022 年和 2030 年北美体外诊断市场收入份额，按应用划分 (%)
  • 传染病
  • 糖尿病
  • 肿瘤学
  • 心臟病学
  • 自体免疫疾病
  • 肾臟病学
  • 其他的

第 9 章：北美体外诊断市场 - 收入和 2030 年预测 - 按最终用户

  • 概述
  • 2022 年及 2030 年北美体外诊断市场收入份额（按最终用户划分）（%）
  • 医院
  • 实验室
  • 居家护理
  • 其他的

第 10 章：北美体外诊断市场 - 2030 年收入与预测 - 国家分析

  • 我们
  • 加拿大
  • 墨西哥

第 11 章：产业格局

  • 有机发展
    • 概述
  • 无机发展
    • 概述

第 12 章：公司简介

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Danaher Corp
  • Siemens AG
  • Sysmex Corp
  • Thermo Fisher Scientific Inc
  • Becton Dickinson and Co
  • bioMerieux SA
  • Bio-Rad Laboratories Inc
  • Qiagen NV

第 13 章：附录

Product Code: TIPRE00022125

The North America in-vitro diagnostics market is expected to grow from US$ 21,207.07 million in 2022 to US$ 33,183.41 million by 2030. It is estimated to grow at a CAGR of 5.8% from 2022 to 2030.

Growth in Point-of-Care Testing and Surge in Demand for IVD during COVID-19 Pandemic Fuels North America In-Vitro Diagnostics Market

Point-of-care testing (POCT) is a pivotal opportunity in the in vitro diagnostics market, revolutionizing healthcare delivery with its potable and rapid diagnostic capabilities. These tests, conducted at or near the patient's location, offer immediate results, enabling timely clinical decision-making. Several factors drive the growth of POCT.

Firstly, the demand for convenient and swift diagnostic solutions in healthcare settings, such as emergency rooms, clinics, and home care, propels the expansion of POCT. Secondly, technological advancements have led to the development of compact and user-friendly POCT devices.

Moreover, the COVID-19 pandemic underscored the significance of rapid and accessible diagnostics. The pandemic accelerated the deployment and utilization of point-of-care COVID-19 tests, showcasing the relevance and potential of POCT in managing infectious diseases on a global scale. This experience accelerated research and development on POCT, further driving innovation and investment in portable testing solutions.

IVDs that are used in the diagnosis of infectious diseases include immunoassays, and molecular assays. Diagnostics companies also focus on making rapid advancements in their offerings to manage COVID-19. Further, regulatory authorities introduced temporary amendments or modifications to their standards, which favored the launches of new IVDs during the pandemic. The demand for molecular diagnostics and immunoassays surged due to these government initiatives. Thus, the COVID-19 pandemic has benefitted the in-vitro diagnostics market due to the rising demand for point-of-care (POC) diagnostics and laboratory testing procedures.

North America In-Vitro Diagnostics Market Overview

North America region includes the US, Canada, and Mexico. It holds the largest share of the in-vitro diagnostics market by geography. All three countries in the region are witnessing considerable demand for in-vitro diagnostics. Certain factors, such as the increasing prevalence of chronic & infectious diseases, focus on efficient disease diagnosis, and a higher need for advanced healthcare systems are boosting the adoption of in-vitro diagnostics in the region. The US held the largest share of the North America in-vitro diagnostics market. Chronic diseases such as cancer and cardiovascular diseases are the major causes of disability and death in the US. Per the National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 people in the country have at least one chronic disease. According to the Centers for Disease Control and Prevention (CDC), in 2021, ~18.2 million adults aged 20 and above had coronary artery disease (CAD) in the US. Heart disease is the leading cause of death among people in the country. Additionally, the American Hospital Association estimates ~133 million people have at least one chronic disease, and that number is expected to reach 170 million by 2030. The high incidence of chronic diseases results in a huge demand for diagnostic procedures, which, in turn, drives the in-vitro diagnostics market in the US. Growing emphasis on preventive care coupled with enhanced access to healthcare facilities would further boost the market growth in the coming years.

With the exponentially rising need for in-vitro diagnostics tools with the growing patient pool, the market players focus on developing advanced diagnostic systems enabling rapid examinations. For instance, in February 2019, Grail, a US-based player in diagnostic services, received financial aid of US$ 1.5 billion from Microsoft and Amazon with an aim to develop new technologies for rapid cancer detection. Additionally, extensive technological advancements due to developed healthcare infrastructure and rising expenditure are generating lucrative opportunities for the growth of the in-vitro diagnostics market in the country. For instance, in July 2019, Sysmex America, Inc., one of the prominent players in the in-vitro diagnostics market, showcased its new integrated in-vitro diagnostic machine named PS-10 at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo organized in Anaheim, California. The machine is designed to perform complex laboratory tests, routine cytometry, and hematology assessments. Similarly, in May 2020, Bio-Rad Laboratories Inc. received Emergency Use Authorization (EUA) for its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit from the US Food and Drug Administration (FDA). The SARS-CoV-2 ddPCR test runs on Bio-Rad's QX200 and QXDx ddPCR systems.

North America In-Vitro Diagnostics Market Revenue and Forecast to 2030 (US$ Million)

North America In-Vitro Diagnostics Market Segmentation

The North America in-vitro diagnostics market is segmented into product & services, technology, application, end user, and country.

Based on product & services, the North America in-vitro diagnostics market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on technology, the North America in-vitro diagnostics market is segmented into immunoassay/ immunochemistry, clinical chemistry, molecular diagnostics, microbiology, blood glucose self-monitoring, coagulation & hemostasis, hematology, urinalysis, and others. The immunoassay/ immunochemistry segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on application, the North America in-vitro diagnostics market is segmented into infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, and others. The infectious diseases segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on end user, the North America in-vitro diagnostics market is segmented into hospitals, laboratories, homecare, and others. The hospitals segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on country, the North America in-vitro diagnostics market is segmented int o the US, Canada, and Mexico. The US dominated the North America in-vitro diagnostics market in 2022.

Abbott Laboratories, Becton Dickinson and Co, bioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Qiagen NV, Siemens AG, Sysmex Corp, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America in-vitro diagnostics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America In-Vitro Diagnostics Market - Key Industry Dynamics

  • 4.1 Key Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic and Infectious Diseases
    • 4.1.2 Growth in Point-of-Care Testing and Surge in Demand for IVD during COVID-19 Pandemic
  • 4.2 Market Restraint
    • 4.2.1 Insufficiency of Regulatory Frameworks and Reimbursement Policies
  • 4.3 Market Opportunities
    • 4.3.1 Integration of IVD with Digital Health Technologies
  • 4.4 Future Trends
    • 4.4.1 Increasing Demand for Personalized Medicine and Genomics

5. In-Vitro Diagnostics Market - North America Market Analysis

  • 5.1 North America In-Vitro Diagnostics Market Revenue (US$ Mn), 2022 - 2030

6. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - by Product and Services

  • 6.1 Overview
  • 6.2 North America In-Vitro Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
  • 6.3 Reagents and Kits
    • 6.3.1 Overview
    • 6.3.2 Reagents and Kits: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Software and Services
    • 6.4.1 Overview
    • 6.4.2 Software and Services: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Instruments
    • 6.5.1 Overview
    • 6.5.2 Instruments: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

7. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - by Technology

  • 7.1 Overview
  • 7.2 North America In-Vitro Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
  • 7.3 Immunoassay/ Immunochemistry
    • 7.3.1 Overview
    • 7.3.2 Immunoassay/ Immunochemistry: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Clinical Chemistry
    • 7.4.1 Overview
    • 7.4.2 Clinical Chemistry: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Molecular Diagnostics
    • 7.5.1 Overview
    • 7.5.2 Molecular Diagnostics: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Microbiology
    • 7.6.1 Overview
    • 7.6.2 Microbiology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Blood Glucose Self-Monitoring
    • 7.7.1 Overview
    • 7.7.2 Blood Glucose Self-Monitoring: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.8 Coagulation and Hemostasis
    • 7.8.1 Overview
    • 7.8.2 Coagulation and Hemostasis: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.9 Hematology
    • 7.9.1 Overview
    • 7.9.2 Hematology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.10 Urinalysis
    • 7.10.1 Overview
    • 7.10.2 Urinalysis: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.11 Others
    • 7.11.1 Overview
    • 7.11.2 Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 North America In-Vitro Diagnostics Market Revenue Share, by Application 2022 & 2030 (%)
  • 8.3 Infectious Disease
    • 8.3.1 Overview
    • 8.3.2 Infectious Diseases: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Diabetes
    • 8.4.1 Overview
    • 8.4.2 Diabetes: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Oncology
    • 8.5.1 Overview
    • 8.5.2 Oncology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Cardiology
    • 8.6.1 Overview
    • 8.6.2 Cardiology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Autoimmune Diseases
    • 8.7.1 Overview
    • 8.7.2 Autoimmune Diseases: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.8 Nephrology
    • 8.8.1 Overview
    • 8.8.2 Nephrology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.9 Others
    • 8.9.1 Overview
    • 8.9.2 Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 North America In-Vitro Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Laboratories
    • 9.4.1 Overview
    • 9.4.2 Laboratories: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Homecare
    • 9.5.1 Overview
    • 9.5.2 Homecare: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

10. North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 - Country Analysis

  • 10.1 North America In-Vitro Diagnostics Market
    • 10.1.1 Overview
    • 10.1.2 North America In-Vitro Diagnostics Market, by Country
      • 10.1.2.1 US: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.1.1 Overview
        • 10.1.2.1.2 US: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.1.3 US: North America In-Vitro Diagnostics Market, by Product and Services, 2020-2030 (US$ Million)
        • 10.1.2.1.4 US: North America In-Vitro Diagnostics Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.2.1.5 US: North America In-Vitro Diagnostics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.2.1.6 US: North America In-Vitro Diagnostics Market, by End User, 2020-2030 (US$ Million)
      • 10.1.2.2 Canada: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.2.1 Overview
        • 10.1.2.2.2 Canada: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.2.3 Canada: North America In-Vitro Diagnostics Market, by Product and Services, 2020-2030 (US$ Million)
        • 10.1.2.2.4 Canada: North America In-Vitro Diagnostics Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.2.2.5 Canada: North America In-Vitro Diagnostics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.2.2.6 Canada: North America In-Vitro Diagnostics Market, by End User, 2020-2030 (US$ Million)
      • 10.1.2.3 Mexico: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.3.1 Overview
        • 10.1.2.3.2 Mexico: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.2.3.3 Mexico: North America In-Vitro Diagnostics Market, by Product and Services, 2020-2030 (US$ Million)
        • 10.1.2.3.4 Mexico: North America In-Vitro Diagnostics Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.2.3.5 Mexico: North America In-Vitro Diagnostics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.2.3.6 Mexico: North America In-Vitro Diagnostics Market, by End User, 2020-2030 (US$ Million)

11. Industry Landscape

  • 11.1 Organic Developments
    • 11.1.1 Overview
  • 11.2 Inorganic Developments
    • 11.2.1 Overview

12. Company Profiles

  • 12.1 Abbott Laboratories
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 F. Hoffmann-La Roche Ltd
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Danaher Corp
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Siemens AG
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Sysmex Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Thermo Fisher Scientific Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Becton Dickinson and Co
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 bioMerieux SA
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Bio-Rad Laboratories Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Qiagen NV
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America In-Vitro Diagnostics Market Segmentation
  • Table 2. US North America In-Vitro Diagnostics Market, by Product and Services - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. US North America In-Vitro Diagnostics Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US North America In-Vitro Diagnostics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. US North America In-Vitro Diagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. Canada North America In-Vitro Diagnostics Market, by Product and Services - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Canada North America In-Vitro Diagnostics Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Canada North America In-Vitro Diagnostics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Canada North America In-Vitro Diagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Mexico North America In-Vitro Diagnostics Market, by Product and Services - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Mexico North America In-Vitro Diagnostics Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Mexico North America In-Vitro Diagnostics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Mexico North America In-Vitro Diagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Organic Developments Done by Companies
  • Table 15. Inorganic Developments Done by Companies
  • Table 16. Glossary of Terms, North America In-Vitro Diagnostics Market

List Of Figures

  • Figure 1. North America In-Vitro Diagnostics Market Segmentation, By Country
  • Figure 2. North America In-Vitro Diagnostics Market: Key Industry Dynamics
  • Figure 3. North America In-Vitro Diagnostics Market: Impact Analysis of Drivers and Restraints
  • Figure 4. North America In-Vitro Diagnostics Market Revenue (US$ Mn), 2020 - 2030
  • Figure 5. North America In-Vitro Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
  • Figure 6. Reagents and Kits: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Software and Services: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Instruments: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America In-Vitro Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
  • Figure 10. Immunoassay/ Immunochemistry: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Clinical Chemistry: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Molecular Diagnostics: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Microbiology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Blood Glucose Self-Monitoring: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Coagulation and Hemostasis: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Hematology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Urinalysis: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. North America In-Vitro Diagnostics Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 20. Infectious Diseases: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Diabetes: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Oncology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Cardiology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Autoimmune Diseases: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Nephrology: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 26. Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 27. North America In-Vitro Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 28. Hospitals: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Laboratories: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 30. Homecare: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Others: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 32. North America: North America In-Vitro Diagnostics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 33. North America In-Vitro Diagnostics Market, by Country, 2022 & 2030 (%)
  • Figure 34. US: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 35. Canada: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 36. Mexico: North America In-Vitro Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)